Everything tagged "ipo" across research, earnings, and macro.
103 articles
Alopexx, Inc. (ALPX) is expected to list on NASDAQ on 2026-07-07, but the company has not disclosed a price range or share count yet. The setup is a binary biotech story: broad anti-infective science with a small cash base, but a long path to pivotal data and more capital.
Iron Dome Acquisition I Corp. Class A Ordinary Shares (NASDAQ: IDAC) is expected to list on 2026-07-06, but the price range has not been disclosed. This is a SPAC, so the real question is whether the sponsor can find a credible target in cybersecurity, defense tech, AI, or data infrastructure. The setup favors investors who want exposure to that theme, but the main watch item is whether the deal terms and target pipeline justify the trust-account structure.
Eos Energy Enterprises, Inc. Right is expected to list on NASDAQ on 2026-07-06, but the price range has not been disclosed. The company is already public under NASDAQ: EOSE, so this is best viewed as a capital-markets event rather than a first-time IPO. Bull case: long-duration storage demand is real; bear case: the business is still loss-making and heavily dependent on financing.
Tarsier Pharma Ltd. (NYSE: TARX) is expected to list on 2026-07-09, with 5,000,000 shares priced at $8.00 to $10.00 each. The company is a late-stage ophthalmic biotech with no product revenue yet, so the setup hinges on clinical progress rather than current sales.
IQM Quantum Computers Oyj American Depositary Shares is expected to list on NASDAQ on 2026-07-02, but the price range has not been disclosed. The deal is a SPAC merger with Real Asset Acquisition Corp. under ticker IQMX. Bull case: a real systems-delivery track record; bear case: quantum remains early, loss-making, and execution-heavy.
Vicore Pharma Holding AB American Depositary Shares are expected to list on NASDAQ on 2026-07-02, with the price range not disclosed yet. This is a U.S. dual listing, not a traditional cash-raising IPO, so the main question is whether the story around buloxibutid is strong enough to attract U.S. investors. The bull case is a first-in-class IPF drug in a large unmet market; the bear case is a clinical-stage company still years from commercialization.
Aeon Acquisition I Corp. Rights (NASDAQ: AESPR) is expected to list on 2026-07-01, but the price range has not been disclosed yet. This is a SPAC, so the story is about sponsor execution and deal-finding, not operating growth. The setup favors investors who want a rights-heavy blank-check structure, but the key question is whether the team can source a credible merger target.
ITG, Inc. Class A Common Stock is expected to list on NASDAQ on 2026-07-01, but the price range has not been disclosed yet. The company is offering 19,512,196 shares. The setup leans on fiber and digital infrastructure demand, but investors should watch leverage, margin pressure, and customer spending risk as pricing comes into view.
Neutron Holdings Inc. (NASDAQ: LIME) is expected to list on 2026-07-01 at a $24.00-$26.00 price range. The company is offering 6,956,522 shares, with the deal sized around a $208 million market cap if disclosed terms hold. The bull case is Lime’s growth and scale; the bear case is regulation, losses, and a business that still depends on city permits.
Idaho Copper Corporation (NYSE, expected 2026-07-01) has not disclosed its price range yet. The company is expected to list on the NYSE as COPR, with terms still pending. The bull case is a large Idaho copper-molybdenum-silver project tied to electrification demand; the bear case is a pre-production developer with no revenue, a going-concern warning, and heavy dilution risk.
Luminar Technologies, Inc. (NYSE: LAZR) is expected to list on 2026-06-30, but the price range has not been disclosed. The setup pits a real LiDAR/autonomy story against persistent losses, customer-program risk, and a crowded sensor market.
Professionally Managed Portfolios - Pabrai Wagons Fund (NYSE: WAGN) is expected to list on 2026-06-30, but the price range has not been disclosed. This is not a traditional operating-company IPO; it is an ETF reorganization that will trade on the NYSE. The setup favors investors who want a concentrated industrial-transportation strategy, but shareholders should watch key-man risk and ETF trading dynamics.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator